Scientific Advisory Board
Joseph M. Davie, M.D., Ph.D.
Dr. Davie has served on the Curis board since July 2003. From 1993 to 2000, he was the Senior Vice President of Research at Biogen, Inc., now Biogen Idec. Prior to joining Biogen, Dr. Davie held several senior positions at G.D. Searle and Co., including Senior Vice President of Science and Technology and President of Research and Development. Dr. Davie serves on the boards of several public and private biotechnology companies. He received his M.D. from the Washington University School of Medicine and his Ph.D. from Indiana University.
Stuart A. Aaronson, M.D.
Dr. Aaronson is currently the Chairman for the Department of Oncological Sciences at The Mount Sinai Medical Center in New York City, and the Jane B. and Jack R. Aron Professor of Neoplastic Diseases at the school. He has been recognized for his accomplishments throughout the years with numerous awards and medals, including the Distinguished Service Medal Award from the U.S. Public Health Service, the Rhoads Memorial Award from the American Association of Cancer Research and the Paul Erhlich Prize from Germany.
Dr. Aaronson is the author of more than 530 publications, an inventor on more than 50 patents and serves on numerous editorial boards and scientific advisory committees.
Kenneth J. Pienta, M.D.
Dr. Pienta is Professor of Internal Medicine and Urology and the Director of the Urologic Oncology program at the University of Michigan Comprehensive Cancer Center. He is also the chair of the Translational Medicine Committee of the Southwest Oncology Group (SWOG). Dr. Pienta has international expertise in the development of novel chemotherapeutic programs for prostate cancer and is the principal investigator on The University of Michigan's SPORE (Specialized Program of Research Excellence) in prostate cancer awarded from the National Cancer Institute. In 2003, Dr. Pienta received the American Cancer Society Clinical Research Professor Award in recognition of his achievements in translational research. He is the author of more than 200 peer-reviewed articles and 50 book chapters.
Currently, Dr. Pienta is involved in research to understand the process of prostate cancer metastasis to bone as well as developing new therapies for prostate cancer.
George F. Vande Woude, Ph.D.
Dr. George F. Vande Woude is the Director of the Van Andel Research Institute in Grand Rapids, Michigan. He spent more than thirty years at the National Cancer Institute in a variety of roles, most notably that of Special Advisor to the Director of the National Cancer Institute and Director of the Division of Sciences (1998-1999), where he reorganized the intramural basic sciences.
Dr. Vande Woude is the author of over 250 scientific research articles and over 60 articles in books or monographs. He has served as Editor of Journal of Virology and as an Editorial Board Member of Cell, Cancer Research, and Journal of Virology and is currently as an Editorial Board Member of Oncogene, Molecular Imaging, Cancer Letters, Cell Cycle and Molecular Cancer Research. Dr. Vande Woude was Founding Editor of Cell Growth and Differentiation and, since 1989, has been Co-editor (with George Klein) of Advances in Cancer Research.
Through the course of his 45-year scientific career, Dr. Vande Woude has mentored more than 70 postdoctoral fellows, students, and visiting scientists. His laboratory has published over 300 research articles that have been referenced on more than 8500 occasions.
